Changeflow GovPing Pharma & Drug Safety Phosphate-containing copolymers for virulence s...
Routine Notice Added Final

Phosphate-containing copolymers for virulence suppression

Favicon for changeflow.com EPO Patent Bulletin - Therapeutics (A61P)
Published
Detected
Email

Summary

The European Patent Office published patent application EP4182377A1 for 3M Innovative Properties Company's phosphate-containing copolymers designed to suppress bacterial virulence. The invention covers copolymer compositions targeting A61P 31/04 (anti-infectives). Designated states cover all EU member states plus additional European countries.

What changed

The EPO published patent application EP4182377A1 disclosing phosphate-containing copolymers for virulence suppression in bacterial infections. The copolymers (classified under C08G 65/335 and A61K 31/765) are designed to inhibit bacterial virulence factors. Inventors include Carl Laskowski, Timothy Gillard, Ranjani Parthasarathy, Hannah Cohen, and Max Kruziki.

Pharmaceutical and biotechnology companies developing anti-infective therapeutics should consider this patent when designing programs targeting bacterial virulence pathways. The designated state coverage (all EU member states plus Switzerland, Norway, and others) means any commercial development of similar phosphate copolymer compositions in Europe may require licensing negotiations with 3M.

What to do next

  1. Monitor for competing patent applications in virulence suppression space
  2. Review Freedom to Operate if developing anti-bacterial copolymers

Archived snapshot

Apr 9, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

PHOSPHATE-CONTAINING COPOLYMERS FOR VIRULENCE SUPPRESSION

Publication EP4182377A1 Kind: A1 Apr 01, 2026

Applicants

3M Innovative Properties Company

Inventors

LASKOWSKI, Carl A., GILLARD, Timothy M., PARTHASARATHY, Ranjani V., COHEN, Hannah C., KRUZIKI, Max A.

IPC Classifications

C08G 65/335 20060101AFI20220121BHEP A61K 31/765 20060101ALI20220121BHEP A61P 31/04 20060101ALI20220121BHEP C08G 65/22 20060101ALI20220121BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4182377A1

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent publication Anti-infective research
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Medical Devices

Get alerts for this source

We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!